NCT01108978

Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease

Phase IV Study for Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Nang Kuang Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the Efficacy and Safety of Dehypotin® in the Patients with Type 2 Diabetes Mellitus or Cardiovascular Disease. Eligible patients will be randomly assigned to 1 of 2 arms, either Dehypotin® or placebo, and will receive the diet advisement throughout the study.

Conditions

• Type 2 Diabetes Mellitus
• Cardiovascular Disease
• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	Placebo	Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
DRUG	Dehypotin	Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-05-01
• Completion: 2011-05-01
• First posted: 2010-04-22
• Last updated: 2011-06-09

Locations

1 site across 1 country: Taiwan